FR2644463A1 - - Google Patents
Download PDFInfo
- Publication number
- FR2644463A1 FR2644463A1 FR8903557A FR8903557A FR2644463A1 FR 2644463 A1 FR2644463 A1 FR 2644463A1 FR 8903557 A FR8903557 A FR 8903557A FR 8903557 A FR8903557 A FR 8903557A FR 2644463 A1 FR2644463 A1 FR 2644463A1
- Authority
- FR
- France
- Prior art keywords
- protein
- polypeptide
- male
- hybrid
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 55
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 33
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 229920000856 Amylose Polymers 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 8
- 230000003472 neutralizing effect Effects 0.000 claims description 7
- 210000001322 periplasm Anatomy 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 1
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 210000004897 n-terminal region Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 abstract description 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 6
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108010041397 CD4 Antigens Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 101150075764 CD4 gene Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108010090127 Periplasmic Proteins Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 125000003071 maltose group Chemical group 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 101100398597 Botryotinia fuckeliana lcc1 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101100068374 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) GIP1 gene Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001529466 Muscardinus avellanarius Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8903557A FR2644463A1 (enExample) | 1989-03-17 | 1989-03-17 | |
| PCT/FR1990/000182 WO1990011360A1 (fr) | 1989-03-17 | 1990-03-16 | POLYPEPTIDE DE FUSION ENTRE UNE AFFINE DU MALTOSE (MalE) ET UN FRAGMENT DE CD4 NEUTRALISANT LES VIRUS HIV. |
| JP2505325A JPH03504729A (ja) | 1989-03-17 | 1990-03-16 | マルトースに対して親和性のある物質（ＭａｌＥ）と、ＨＩＶウイルスに対する中和特性を有するＣＤ４タンパク質フラグメントとの融合によって生じた融合ＣＤ４ポリペプチド |
| EP19900905557 EP0426787A1 (fr) | 1989-03-17 | 1990-03-16 | POLYPEPTIDE DE FUSION ENTRE UNE AFFINE DU MALTOSE (MalE) ET UN FRAGMENT DE CD4 NEUTRALISANT LES VIRUS HIV. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8903557A FR2644463A1 (enExample) | 1989-03-17 | 1989-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2644463A1 true FR2644463A1 (enExample) | 1990-09-21 |
Family
ID=9379821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8903557A Withdrawn FR2644463A1 (enExample) | 1989-03-17 | 1989-03-17 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0426787A1 (enExample) |
| JP (1) | JPH03504729A (enExample) |
| FR (1) | FR2644463A1 (enExample) |
| WO (1) | WO1990011360A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851828A (en) * | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5843728A (en) * | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0299810A1 (fr) * | 1987-05-18 | 1989-01-18 | Institut Pasteur | Procédé de préparation de polypeptides par ADN recombinant |
-
1989
- 1989-03-17 FR FR8903557A patent/FR2644463A1/fr not_active Withdrawn
-
1990
- 1990-03-16 EP EP19900905557 patent/EP0426787A1/fr not_active Withdrawn
- 1990-03-16 WO PCT/FR1990/000182 patent/WO1990011360A1/fr not_active Ceased
- 1990-03-16 JP JP2505325A patent/JPH03504729A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0299810A1 (fr) * | 1987-05-18 | 1989-01-18 | Institut Pasteur | Procédé de préparation de polypeptides par ADN recombinant |
Non-Patent Citations (3)
| Title |
|---|
| COMPTES RENDUS DE L'ACADEMIE DES SCIENCES DE PARIS, vol. 308, no. 14, série III, 6 avril 1989, pages 401-406, Académie des Sciences; J.-M. CLEMENT et al.: "Propriétés neutralisantes pour le virus HIV d'une protéine hybride Ma1E-CD4 exprimée chez E. coli et purifiable en une étape" * |
| GENE, vol. 74, no. 2, 30 décembre 1988, pages 365-373, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, NL; C.V. MAINA et al.: "An Escherichia coli vector to express and purify foreign proteins by fusion and separation from maltose-binding protein" * |
| NATURE, vol. 335, no. 6188, 22 septembre 1988, pages 369-372, Londres, GB; Y.K. CHAUDHARY et al.: "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein" * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03504729A (ja) | 1991-10-17 |
| WO1990011360A1 (fr) | 1990-10-04 |
| EP0426787A1 (fr) | 1991-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2285706T3 (es) | Tecnologia de expresion y exportacion de proteinas como inmunofusinas. | |
| EP0759944B1 (en) | Target cell binding chimaeric peptides | |
| CA2298934C (fr) | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules | |
| FR2766193A1 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
| CA2218759A1 (fr) | Nouveaux variants de l'apolipoproteine a-i | |
| FR2644463A1 (enExample) | ||
| WO1997002840A1 (fr) | Immunovecteurs utilisables pour le transport intracellulaire et intranucleaire | |
| EP1368372B1 (fr) | Peptides presentant une affinite pour la proteine virale gp120, et utilisation de ces peptides | |
| WO2014057437A2 (fr) | Procede de preparation de proteine c1q recombinante | |
| CA2125877A1 (fr) | Polypeptides derives de l'apolipoproteine aiv humaine, leur preparation et leur utilisation | |
| EP0439601B1 (fr) | Composition contenant un epitope b de la glycoproteine d'enveloppe d'un retrovirus et un epitope t d'une proteine distincte de ce retrovirus | |
| EP0842282A1 (fr) | Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp | |
| FR2816845A1 (fr) | Vecteurs de transport a travers un epithelium a jonctions serrees | |
| FR2635532A1 (fr) | Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant | |
| EP1735344A1 (fr) | Composition de vaccin comprenant un ligan cmh de classe ii couple a un antigene, procede de preparation et utilisations | |
| WO1988009375A1 (fr) | Procede de preparation de polypeptides par adn recombinants | |
| CA2528186A1 (fr) | Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation | |
| CA2540520A1 (fr) | Polypeptide d'interaction comprenant un motif heptapeptidique et un domaine de penetration cellulaire | |
| FR2694938A1 (fr) | Nouveaux peptides, anticorps dirigés contre ces peptides, anticorps anti-idiotypiques, application à titre de médicaments, compositions pharmaceutiques et kits de diagnostic les renfermant. | |
| JPH08503704A (ja) | Ｇｐ４１変異体とｈｉｖ治療剤としてのそれらの使用 | |
| JP2813630B2 (ja) | ヒト免疫不全ウイルスのエンベロープポリペプチドおよびその抗体 | |
| Chen | Study of Nef-induced Enhancement of HIV-1 Infectivity and CD4 Down-regulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ER | Errata listed in the french official journal (bopi) |
Free format text: 38/90 |
|
| ST | Notification of lapse |